Curosurf (Poractant Alfa)

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product helps improve lung function and oxygenation, making it a critical treatment in neonatal care.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs do not produce enough surfactant, a substance that keeps the air sacs open. By providing external surfactant, Curosurf helps to reduce the surface tension in the lungs, facilitating easier breathing and improving oxygen levels. It is administered directly into the lungs via endotracheal tube.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce the effort required to inflate the lungs and maintain their openness. This can lead to improved breathing and oxygenation in premature infants with respiratory distress syndrome. The effects are typically observed soon after administration.

Curosurf should be administered by healthcare professionals experienced in neonatal intensive care. It is important to follow proper handling and storage guidelines to ensure the product's effectiveness. Always consult a healthcare provider for specific instructions and precautions related to its use.

Curosurf is generally used in a controlled medical setting, and interactions with other medications are not commonly reported. However, it is important to inform healthcare providers about any other treatments the infant is receiving to avoid potential complications.